Drug Discovery & Preclinical
- Drug Discovery & Preclinical
- Monoclonal Antibodies
- Antibody-Drug Conjugates
- Vaccines (Prophylactic & Therapeutic)
- Cell & Gene Therapies (CGT)
- Allergy & Hypersensitivity
- Biomarker
- High-Dimensional Single-Cell Analysis by Flow Cytometry
- High-Throughput Cytokine & Chemokine Profiling by Multiplexing
- Biomarkers via Advanced IHC & Spatial Imaging
- Rare Cellular Functional Biomarkers by ELISPOT
- Real-Time Kinetic Biomarkers by IncuCyte S3
- Genomic Biomarker Analysis by qPCR & Droplet Digital PCR
- Seahorse XF: Immunometabolism & Bioenergetics
- MALDI Biotyper: Rapid Microbial & Proteomic Profiling
- Sapidyne KinExA
- Robust Protein Quantification by ELISA
- Advanced LNP Formulation & Screening – Unchained Labs Sunshine
- Translational & Clinical Research
- Immunogenicity Risk Assessment & Immunotoxicology
- Regulated Bioanalysis: PK, PD & Soluble Biomarkers
- Histopathology & Spatial Biology
- Advanced Flow Cytometry & Cellular Immunology
- Molecular Bioanalysis & Genomic Profiling
- Functional Potency & Ex Vivo Translational Models
- Central Laboratory & Clinical Trial Sample Management
- Dermo-Cosmetics & FMCG
- Nutraceuticals & Wellness
- Biorepository
Empowering Your Path to IND Submission
We bridge the gap between your early-stage concept and a successful IND submission by delivering more than just standard analytical assays, we provide a clear, dynamic understanding of complex immune modulation.
As modern therapeutics evolve far beyond traditional small molecules, navigating the biological intricacies of next-generation modalities requires specialized precision. In preclinical development, the margin for error is razor-thin. That is why we focus on generating robust, decision-grade data that accurately predicts how your therapeutic will interact with the immune system in vivo.
Whether you are validating a novel biologic or evaluating translational safety, we deliver the actionable evidence required to confidently advance your most promising assets toward the clinic.